SCHEMBL6246264

SCHEMBL6246264

CC(=O)[N]Cc1ccc(Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HTT P42858 2/20 0.44
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TAAR1 Q96RJ0 2/20 0.43
CTBP2 P56545 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
ALDH1A1 P00352 5/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
CYP2C19 P33261 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
EGFR P00533 1/20 0.40
ERBB2 P04626 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4588101 0.79 TAAR1 (0.52) MEN1KMT2ALMNATAAR1CTBP2
SCHEMBL6544369 0.79 HTR3E (0.53) TAAR1CTBP2MAOAMAOB
SCHEMBL1040588 0.78 NOS2 (0.50) LMNASMN1; SMN2CTBP2ALDH1A1KDM4E
SCHEMBL2090624 0.72 IDO1 (0.48) MEN1KMT2ALMNATAAR1SLC6A4
SCHEMBL2096441 0.72 POLB (0.48) LMNASMN1; SMN2L3MBTL1ALDH1A1RAB9A
SCHEMBL48823 0.71 L3MBTL1 (0.55) MEN1KMT2AHTTLMNASMN1; SMN2
SCHEMBL2094716 0.71 SMN1; SMN2 (0.45) KMT2ALMNASMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL12121938 0.70 IDO1 (0.46) MEN1KMT2ALMNATAAR1CTBP2
Hydrochloric Acid SCHEMBL27891675 0.70 L3MBTL1 (0.53) MEN1KMT2AHTTLMNASMN1; SMN2
Acetic Acid SCHEMBL27587482 0.70 MEN1 (0.47) MEN1KMT2AHTTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171132-A1 Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists XIN ZHILI (US) 2005-08-04 US disclosed
US-20050171131-A1 Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists KOSOGOF CHRISTI (US) 2005-08-04 US disclosed
WO-2005030734-A1 DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS ABBOTT LABORATORIES (US) 2005-04-07 WO disclosed
US-20050070712-A1 Pyrimidine derivatives as ghrelin receptor modulators ABBOTT LABORATORIES 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171131-A1 Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists GHSR, GIPR, GPR119 MEN1 1738/4885KMT2A 950/4885HTT 2226/4885
US-20050171132-A1 Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists GHSR, GIPR, GPR119 MEN1 1865/4885KMT2A 1065/4885HTT 2342/4885
US-20050070712-A1 Pyrimidine derivatives as ghrelin receptor modulators GPR119, GIPR, GCGR MEN1 3951/4885KMT2A 2596/4885HTT 3165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.